ANGI-09 COMPARISON OF PROGRESSION PATTERN (PP) AND ADVERSE EVENTS (AES) WITH USE OF BEVACIZUMAB (BEV) ACROSS MULTIPLE LINES IN THE TREATMENT IN GLIOBLASTOMA (GBM)

Documenti analoghi

• ANGI-13 HISTOPATHOLOGICAL INVESTIGATION OF GLIOBLASTOMAS RESECTED UNDER CONTROL OF NEOADJUVANT BEVACIZUMAB
  di: Tamura, Ryota, et al.
  Pubblicazione: (2015)
• ANGI-07 MR-PERFUSION DERIVED HEMODYNAMIC PARAMETRIC RESPONSE MAPPING OF BEVACIZUMAB EFFICACY IN RECURRENT GLIOBLASTOMA
  di: Kickingereder, Philipp, et al.
  Pubblicazione: (2015)
• QOL-16 HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN A PHASE II TRIAL OF HYPOFRACTIONATED INTENSITY-MODULATED RADIATION THERAPY (HYPO-IMRT) WITH TEMOZOLOMIDE (TMZ) AND BEVACIZUMAB (BEV) FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
  di: Mohler, Alexander, et al.
  Pubblicazione: (2015)
• Progression pattern and adverse events with bevacizumab in glioblastoma
  di: Mamo, A., et al.
  Pubblicazione: (2016)
• ANGI-09. δ-Catenin Regulates Bevacizumab-Induced Glioma Invasion
  di: Shimizu, Toshihiko, et al.
  Pubblicazione: (2017)